Press releases
Novasep signs a manufacturing services agreement with Exelixis for a next-generation ADC
• The agreement covers the cGMP clinical manufacturing of a next-generation ADC drug candidate
• Novasep’s Le Mans site, in France, has already manufactured the ADC for Exelixis’ ongoing phase 1 clinical trial
• Novasep leverages its ADC bioconjugation expertise and process development capabilities in support of promising new cancer treatments
Novasep invests €6.1 million to upgrade its manufacturing facility for Active Pharmaceutical Ingredients at its Mourenx site
• Novasep continues its investment strategy by upgrading its API manufacturing facility at its Mourenx site, increasing its flexibility and competitiveness
• A €6.1 million investment will be made over 3 years
• This investment has been selected by the French Government to be supported by ‘France Relance’, the post-Covid recovery plan
• 7 full-time jobs to be created
Le Campus Biotech Digital s’allie à Atos, IBM et Microsoft pour le développement d’une plateforme de formation unique au monde
Une nouvelle étape pour l’avancée d’un projet innovant et structurant au service de la Bioproduction de santé française
Novasep expands its HPAPI manufacturing capacity in Le Mans for innovative cancer therapies
• Novasep continues to consolidate its position as a leading CDMO for the production of innovative and targeted molecules to treat cancer by investing in additional capacity
• Responds to increasing customer demand for manufacturing services for Antibody Drug Conjugates (ADCs)
• More than 30 full-time jobs to be created
Novasep announces strong growth in 2020, in an exceptional context, demonstrating the robustness of its strategic model
• The Group recorded sales of €394M (+46%) and an EBITDA of €63M (+174%)
• Novasep has now completed its Rise-2 strategic plan, a full two years ahead of schedule
• Full deleveraging is in progress following the divestment of the Viral Vector Manufacturing Business in early 2021
Novasep announces results of notes offer for its outstanding euro-denominated unsecured exchange notes due 2022
Novasep Holding S.A.S. (“Novasep”) has today announced the results of its offer to purchase (the “Notes Offer”) any and all of its outstanding euro-denominated unsecured exchange notes due 2022 (the “Notes”).
Novasep announces notes offer for its outstanding euro-denominated unsecured exchange notes due 2022 and concurrent optional redemption
Novasep Holding S.A.S. (“Novasep”) has today commenced an offer to purchase (the “Notes Offer”) any and all of its outstanding euro-denominated unsecured exchange notes due 2022 (the “Notes”).
Le Campus Biotech Digital s’allie aux écoles et organismes de formation en biotechnologie pour développer les talents de demain
Une alliance inédite au service de la filière de Bioproduction française
NOVASEP and BONUMOSE announce a strategic collaboration for high-purity rare sugars processing scale-up in Virginia, USA
The collaboration covers the design, engineering and commissioning of a complete process line to produce High Purity Rare Sugars such as Tagatose and Allulose.